Dss (DSS) Stock News

Impact Biomedical, a subsidiary of DSS, announced a positive report on its compound Equivir's international patentability for treating viral infections. The Patentability Report from WIPO indicated no prior art blocking patent claims for Equivir, which may limit viral outbreaks. This marks the third positive step for Equivir, following two U.S. patents awarded for its efficacy against influenza, Ebola, and rhinovirus. Equivir operates by blocking viruses from entering host cells and has potential applications against multiple viral infections, including SARS COV2.

DSS, Inc. (NYSE American: DSS) announced a transformative year ahead, supported by a substantial restructuring since late 2019. The firm boasts over $219 million in assets, including $69 million in cash. Aiming for a breakout year, DSS plans to acquire True Partner Capital, enhancing its global securities business. Recent public offerings generated over $121 million, aiding in strategic medical real estate acquisitions with yields around 8%. DSS expresses optimism about significant growth and potential IPOs in 2022, reflecting the company’s diverse portfolio and commitment to shareholder value.

DSS, Inc. (NYSE American: DSS) announces a letter to shareholders highlighting its transformative journey since 2019. The company's assets have surged from $16.2 million to over $219 million, fueled by acquisitions and divestitures. DSS plans an acquisition of True Partner Capital, boosting its securities business with $1.7 billion in assets under management. The company has raised over $121 million through public offerings and is pursuing spinoffs to enhance shareholder value. With strong growth in medical real estate and direct selling, DSS anticipates significant revenue increases in 2022.

DSS, a multinational company with diverse business interests, will present at the Aegis Capital Corp. Virtual Conference on February 25 at 9:30 a.m. EST. The conference is scheduled from February 23 to 25, operating daily from 8:30 a.m. to 5 p.m. EST. Interested parties can access DSS's presentation by requesting it through Aegis during the conference. DSS operates in sectors such as blockchain security, healthcare, and renewable energy, focusing on sustainable growth and value creation through innovative solutions.

DSS, Inc. (NYSE American: DSS) has entered a stock purchase agreement with Alset EHome International, Inc. to issue up to 44,619,423 shares at $0.3810 each, pending shareholder approval. CEO Frank D. Heuszel described this as a strong vote of confidence that will enhance the company's balance sheet, enabling it to pursue growth opportunities across multiple sectors. COO Jason Grady emphasized the efforts to build a foundation for shareholder value creation, gearing up for the next phase of growth focused on top-line and bottom-line performance.

DSS has announced a significant acquisition by adding True Partner Capital with assets under management (AUM) of $1.7 billion into its financial services arm, DSS Securities. The acquisitions include 877 million shares from Alset EHome International in exchange for newly issued shares of DSS. Following these transactions, Alset will become the majority shareholder with a 55.52% stake. This strategic move aims to enhance growth in DSS's securities business and leverage True Partner's established platform for tailored customer solutions.

DSS, Inc. has announced its subsidiary, American Medical REIT Inc. (AMRE), acquired a 21,900 sq. ft. medical office building in Winter Haven, Florida. The primary tenant, Palm Medical Center, has a six-year lease with 1% annual rent increases. The acquisition enhances AMRE's portfolio, which now exceeds 380,000 sq. ft. of healthcare assets. Additionally, AMRE received a $4.8 million loan from American Pacific Bancorp, with detachable warrants for common stock at $10/share. This move underscores DSS's strategy in resilient medical real estate despite pandemic challenges.

Impact Biomedical, a subsidiary of DSS, has announced the development of eco-friendly bio-plastics designed to resist viruses and reduce environmental impact. Founder Daryl Thompson and his team are isolating natural compounds to enhance plastics' resistance to harmful microorganisms.

Early tests show promising anti-microbial effects against SARS-CoV-2, achieving a 90% reduction in 30 minutes and 99% in 2 hours. These bioplastics aim to address global plastic pollution and have potential applications in various sectors, with the antimicrobial market projected to reach $17.55 billion by 2026.

Value Exchange International, Inc. (OTCQB: VEII) has appointed Mr. Heng Fai Ambrose Chan to its Board of Directors as a non-executive director. Mr. Chan brings over 45 years of experience in financial restructuring and corporate transformation, having successfully restructured more than 35 companies across various sectors. Notably, five of these companies have a combined market capitalization exceeding USD 18 billion and generate over USD 1.4 billion in annual profits. This appointment is expected to enhance the company's leadership and strategic direction.